Literature DB >> 6409127

Determination of the benzodiazepine antagonist Ro 15-1788 in plasma by high-performance liquid chromatography with UV detection.

U Timm, M Zell.   

Abstract

A sensitive and specific HPLC-assay was developed for the determination of the benzodiazepine antagonist ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-[1,5-a] [1,4]benzodiazepine-3-carboxylate (Ro 15-1788; envisaged INN: flumazepil) in plasma. Ro 15-1788 and the internal standard were extracted from plasma at a basic pH, separated from coextracted plasma components on a reversed-phase column and quantitated by means of a UV detector. Ro 15-1788 was extracted quantitatively from plasma in the concentration range 25.6 to 300 ng/ml. The sensitivity limit was about 10 ng/ml plasma using a 1-ml specimen. The method was shown to be specific with respect to several benzodiazepines and their main metabolites. The method was successfully applied to pharmacokinetic studies in man after oral and intravenous administration of Ro 15-1788.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409127

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

1.  Chronic treatment with Ro 15-1788 distinguishes between its benzodiazepine antagonist, agonist and inverse agonist properties.

Authors:  S E File; J Dingemanse; H L Friedman; D J Greenblatt
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

Authors:  G Roncari; W H Ziegler; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

3.  Stability and pharmacokinetics of flumazenil in the rat.

Authors:  J W Mandema; J M Gubbens-Stibbe; M Danhof
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.

Authors:  U Klotz; G Ziegler; I W Reimann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Changes in noradrenaline plasma levels and behavioural responses induced by benzodiazepine agonists with the benzodiazepine antagonist Ro 15-1788.

Authors:  T Duka; M Ackenheil; J Noderer; A Doenicke; R Dorow
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788.

Authors:  U Klotz; T Duka; R Dorow; A Doenicke
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.